Kiniksa will now focus its development efforts on the IL-1 blocker KPL-387, which it is testing for recurrent pericarditis ...
Researchers have discovered a virus that could enter human cells in a similar way to COVID-19. But they caution it's much ...
Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...
USA: Researchers have found in a new study that a respiratory syncytial virus (RSV) prevention strategy combining prenatal ...
Medpage Today on MSN1d
For Your Patients: Navigating Treatment Options in Early Stage Alzheimer’s DiseaseWith early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow ...
Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal ...
The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...
In a small study, Yale researchers have found "differences in immune profiles" among those who have rare reaction to the ...
News Medical on MSN4d
Harbour BioMed partners with Insilico to accelerate AI-powered antibody discoveryHarbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and ...
Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 –– KPL-387 Phase 1 single ascending dose ...
Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer’s Disease ...
The CDC said in a statement on Monday that it does not believe the new coronavirus found in bats poses a concern to public health currently.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback